Takeda Pharmaceutical Company Limited (TAK)
After hours:
| Previous close | 13.10 |
| Open | 13.07 |
| Bid | 12.93 x 1800 |
| Ask | 13.60 x 2200 |
| Day's range | 13.05 - 13.20 |
| 52-week range | 12.77 - 16.39 |
| Volume | |
| Avg. volume | 1,555,865 |
| Market cap | 41.58B |
| Beta (5Y monthly) | 0.51 |
| PE ratio (TTM) | 45.41 |
| EPS (TTM) | 0.29 |
| Earnings date | 31 July 2024 |
| Forward dividend & yield | 0.64 (4.87%) |
| Ex-dividend date | 28 Sept 2023 |
| 1y target est | 18.15 |
Business WireTakeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
OSAKA, Japan & CAMBRIDGE, Mass., June 17, 2024--Takeda (TSE:4502/NYSE:TAK) today announced topline data from its SKYLINE and SKYWAY studies.
Business WireTakeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
OSAKA, Japan & CAMBRIDGE, Mass., June 14, 2024--Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers. If exercised, the option would allow Takeda to license global rights to develop and commerc
Business WireTakeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
CAMBRIDGE, Mass., June 11, 2024--Takeda (TSE:4502/NYSE:TAK) announced that it has expanded its partnership with Partners In Health (PIH), an international nonprofit organization, to support a new initiative with PIH that aims to address social determinants of health and improve access to care within communities across Massachusetts. This builds on Takeda’s existing global partnership with PIH that has been in place since 2017.
